{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:48:32Z","timestamp":1792759712144,"version":"4.5.0"},"reference-count":37,"publisher":"BMJ","issue":"10","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>Myopia is associated with an increased risk of permanent vision loss. The caffeine metabolite 7-methylxanthine (7-MX), licensed in Denmark since 2009 as a treatment to reduce the rate of childhood myopia progression, is the only orally administered therapy available. The purpose of the current study was to assess the rate of myopia progression in children taking 7-MX.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Longitudinal cycloplegic refraction and axial length data for 711 myopic children from Denmark treated with varying doses of oral 7-MX (0\u20131200\u2009mg per day) were analysed using linear mixed models.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The median age at baseline was 11.1 years (range 7.0 \u201315.0 years). Children were followed for an average of 3.6 years (range 0.9\u20139.1 years) and the average myopia progression was 1.34 dioptres (D) (range \u22126.50 to +0.75 D). Treatment with 7-MX was associated with a reduced rate of myopia progression (p&lt;0.001) and axial elongation (p&lt;0.002). Modelling suggested that, on average, an 11-year-old child taking 1000\u2009mg 7-MX daily would develop \u22121.43 D of myopia over the next 6 years, compared with \u22122.27 D if untreated. Axial length in this child would increase by 0.84\u2009mm over 6 years when taking a daily dose of 1000\u2009mg of 7-MX, compared with 1.01\u2009mm if untreated. No adverse effects of 7-MX therapy were reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Oral intake of 7-MX was associated with reduced myopia progression and reduced axial elongation in this sample of myopic children from Denmark. Randomised controlled trials are needed to determine whether the association is causal.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bjo-2021-320920","type":"journal-article","created":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T00:00:13Z","timestamp":1661212813000},"page":"1538-1544","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":30,"title":["Oral administration of caffeine metabolite 7-methylxanthine is associated with slowed myopia progression in Danish children"],"prefix":"10.1136","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1910-9746","authenticated-orcid":false,"given":"Klaus","family":"Trier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5709-9767","authenticated-orcid":false,"given":"Dongmei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren","family":"Ribel-Madsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5164-340X","authenticated-orcid":false,"given":"Jeremy","family":"Guggenheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,8,22]]},"reference":[{"key":"2023092102150606000_107.10.1538.1","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41572-020-00231-4","article-title":"Myopia","volume":"6","author":"Baird","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2023092102150606000_107.10.1538.2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/ICL.0000000000000223","article-title":"Complications of pathologic myopia","volume":"42","author":"Cho","year":"2016","journal-title":"Eye Contact Lens"},{"key":"2023092102150606000_107.10.1538.3","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-72240-y","article-title":"Axial growth and refractive change in white European children and young adults: predictive factors for myopia","volume":"10","author":"McCullough","year":"2020","journal-title":"Sci Rep"},{"key":"2023092102150606000_107.10.1538.4","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.18-25958"},{"key":"2023092102150606000_107.10.1538.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100923"},{"key":"2023092102150606000_107.10.1538.6","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1038\/s41433-020-1122-7","article-title":"A 3-year follow-up study of atropine treatment for progressive myopia in Europeans","volume":"34","author":"Polling","year":"2020","journal-title":"Eye"},{"key":"2023092102150606000_107.10.1538.7","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/cxo.12967","article-title":"Which low-dose atropine for myopia control?","volume":"103","author":"Khanal","year":"2020","journal-title":"Clin Exp Optom"},{"key":"2023092102150606000_107.10.1538.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.12.011"},{"key":"2023092102150606000_107.10.1538.9","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/j.1755-3768.2009.01688.x","article-title":"Effects of 7-methylxanthine on the sclera in form deprivation myopia in guinea pigs","volume":"89","author":"Cui","year":"2011","journal-title":"Acta Ophthalmol"},{"key":"2023092102150606000_107.10.1538.10","first-page":"133","article-title":"Effects of 7-methylxanthine on form-deprivation myopia in pigmented rabbits","volume":"5","author":"Nie","year":"2012","journal-title":"Int J Ophthalmol"},{"key":"2023092102150606000_107.10.1538.11","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1167\/iovs.17-22337","article-title":"The adenosine receptor antagonist, 7-methylxanthine, alters Emmetropizing responses in infant macaques","volume":"59","author":"Hung","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2023092102150606000_107.10.1538.12","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1159\/000502529","article-title":"Effects of 7-methylxanthine on deprivation myopia and retinal dopamine release in chickens","volume":"63","author":"Liu","year":"2020","journal-title":"Ophthalmic Res"},{"key":"2023092102150606000_107.10.1538.13","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2021.108438","article-title":"Topically instilled caffeine selectively alters emmetropizing responses in infant rhesus monkeys","volume":"203","author":"Smith","year":"2021","journal-title":"Exp Eye Res"},{"key":"2023092102150606000_107.10.1538.14","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.83.12.1370"},{"key":"2023092102150606000_107.10.1538.15","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s12177-008-9013-3","article-title":"Systemic 7-methylxanthine in retarding axial eye growth and myopia progression: a 36-month pilot study","volume":"1","author":"Trier","year":"2008","journal-title":"J Ocul Biol Dis Infor"},{"key":"2023092102150606000_107.10.1538.16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/01480545.2019.1635615","article-title":"Pre-Clinical and cellular toxicity evaluation of 7-methylxanthine: an investigational drug for the treatment of myopia","volume":"44","author":"Singh","year":"2021","journal-title":"Drug Chem Toxicol"},{"key":"2023092102150606000_107.10.1538.17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/01480545.2020.1833904","article-title":"Sub-Chronic and chronic toxicity evaluation of 7-methylxanthine: a new molecule for the treatment of myopia","volume":"45","author":"Singh","year":"2022","journal-title":"Drug Chem Toxicol"},{"key":"2023092102150606000_107.10.1538.18","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.14-15839"},{"key":"2023092102150606000_107.10.1538.19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1005432"},{"key":"2023092102150606000_107.10.1538.20","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.14-15474"},{"key":"2023092102150606000_107.10.1538.21","doi-asserted-by":"publisher","DOI":"10.1038\/srep25853"},{"key":"2023092102150606000_107.10.1538.22","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.61.3.20"},{"key":"2023092102150606000_107.10.1538.23","doi-asserted-by":"crossref","unstructured":"Pinheiro JC , Bates DM . Mixed effects models in S and S-Plus. New York, U.S.A: Springer, 2000.","DOI":"10.1007\/978-1-4419-0318-1"},{"key":"2023092102150606000_107.10.1538.24","doi-asserted-by":"publisher","DOI":"10.1093\/pan\/mpi014"},{"key":"2023092102150606000_107.10.1538.25","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1600-0420.1995.tb00294.x","article-title":"Myopia in teenagers. An eight-year follow-up study on myopia progression and risk factors","volume":"73","author":"Jensen","year":"1995","journal-title":"Acta Ophthalmol Scand"},{"key":"2023092102150606000_107.10.1538.26","first-page":"1","article-title":"Myopia progression in young school children. A prospective study of myopia progression and the effect of a trial with bifocal lenses and beta blocker eye drops","volume":"69","author":"Jensen","year":"1991","journal-title":"Acta Ophthalmol Suppl"},{"key":"2023092102150606000_107.10.1538.27","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/APO.0000000000000414","article-title":"A meta-analysis assessing change in pupillary diameter, accommodative amplitude, and efficacy of atropine for myopia control","volume":"10","author":"Tran","year":"2021","journal-title":"Asia Pac J Ophthalmol"},{"key":"2023092102150606000_107.10.1538.28","first-page":"523","article-title":"Distribution of adenosine receptors in human sclera fibroblasts","volume":"14","author":"Cui","year":"2008","journal-title":"Mol Vis"},{"key":"2023092102150606000_107.10.1538.29","first-page":"1139","article-title":"Expression of adenosine receptors in human retinal pigment epithelium cells in vitro","volume":"124","author":"Wan","year":"2011","journal-title":"Chin Med J"},{"key":"2023092102150606000_107.10.1538.30","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.exer.2018.05.020","article-title":"Adenosine receptor distribution in rhesus monkey ocular tissue","volume":"174","author":"Beach","year":"2018","journal-title":"Exp Eye Res"},{"key":"2023092102150606000_107.10.1538.31","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cdd.4402132"},{"key":"2023092102150606000_107.10.1538.32","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006901005925"},{"key":"2023092102150606000_107.10.1538.33","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3390\/biomedicines8040078","article-title":"Atropine differentially modulates ECM production by ocular fibroblasts, and its ocular surface toxicity is blunted by colostrum","volume":"8","author":"Cristaldi","year":"2020","journal-title":"Biomedicines"},{"key":"2023092102150606000_107.10.1538.34","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/978-3-642-13443-2_18","article-title":"Methylxanthines and inflammatory cells","volume":"200","author":"Hask\u00f3","year":"2011","journal-title":"Handb Exp Pharmacol"},{"key":"2023092102150606000_107.10.1538.35","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.pharmthera.2019.01.003","article-title":"The adenosine A 2B G protein-coupled receptor: Recent advances and therapeutic implications","volume":"198","author":"Vecchio","year":"2019","journal-title":"Pharmacol Ther"},{"key":"2023092102150606000_107.10.1538.36","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ebiom.2018.01.024","article-title":"Allergic Conjunctivitis-induced retinal inflammation promotes myopia progression","volume":"28","author":"Wei","year":"2018","journal-title":"EBioMedicine"},{"key":"2023092102150606000_107.10.1538.37","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1721443115"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjo-2021-320920","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T09:20:28Z","timestamp":1695288028000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjo-2021-320920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,22]]},"references-count":37,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,9,21]]},"published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1136\/bjo-2021-320920"],"URL":"https:\/\/doi.org\/10.1136\/bjo-2021-320920","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,22]]}}}